Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein‐mediated drug interaction?
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 89, Issue 7, Pages 2309-2315
Publisher
Wiley
Online
2023-02-06
DOI
10.1111/bcp.15684
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2 , and CYP2C9 and statin‐associated musculoskeletal symptoms
- (2022) Rhonda M. Cooper‐DeHoff et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Comprehensive Pharmacogenomic Study Indicates Roles for SLCO1B1, ABCG2, and SLCO2B1 in Rosuvastatin Pharmacokinetics
- (2022) Minna Lehtisalo et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Functional in vitro characterization of SLCO1B1 variants and simulation of the clinical pharmacokinetic impact of impaired OATP1B1 function.
- (2022) Wilma Kiander et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction
- (2022) Zahra Lotfollahi et al. PLoS One
- THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors
- (2021) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Comparative Hepatic and Intestinal Metabolism and Pharmacodynamics of Statins
- (2021) Anne M. Filppula et al. DRUG METABOLISM AND DISPOSITION
- Acute kidney injury and rhabdomyolysis due to ticagrelor and rosuvastatin
- (2021) Luke P. Parish et al. NURSE PRACTITIONER
- Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin
- (2020) Minna Lehtisalo et al. CTS-Clinical and Translational Science
- Quantitative contribution of six major transporters to the hepatic uptake of drugs: 'SLC-phenotyping' using primary human hepatocytes
- (2019) Yi-an Bi et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients’ Pharmacogenetic Profile
- (2018) Majda Vrkić Kirhmajer et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Ticagrelor-induced acute kidney injury can increase serum concentration of statin and lead to concurrence of rhabdomyolysis
- (2018) In Seong Park Anatolian Journal of Cardiology
- Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions
- (2017) Hsin-Fang Wu et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin
- (2014) Thomayant Prueksaritanont et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1
- (2012) R Elsby et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Transporter Pharmacogenetics and Statin Toxicity
- (2009) M Niemi CLINICAL PHARMACOLOGY & THERAPEUTICS
- Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
- (2009) Jenni E Keskitalo et al. PHARMACOGENOMICS
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started